| John D Fichtenkort, MD | |
|
600 Coffee Rd, Modesto, CA 95355-4201 | |
| (209) 524-1211 | |
| Not Available |
| Full Name | John D Fichtenkort |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 40 Years |
| Location | 600 Coffee Rd, Modesto, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265611768 | NPI | - | NPPES |
| 00G575910 | Medicaid | CA |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sutter Valley Medical Foundation | 9830094515 | 1840 |
News Archive
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
The predominance of men among patients admitted to psychiatric hospitals because of alcohol abuse has declined compared with 25 years ago in Iceland, while the gender gap for other substance use disorders has not changed, say researchers.
A research team led by Dr Alisoun Milne, a Senior Lecturer at the Tizard Centre, University of Kent, has identified weaknesses in the most widely employed dementia screening instrument currently used in primary care.
Cascade Chemistry, a leading contract research and manufacturing organization serving the pharmaceutical, materials, and chemical industries, today announced that it has been selected to produce the active pharmaceutical ingredient for clinical trial supplies of RBT-9, an investigational therapy entering a Phase 2 trial for the treatment of COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as kidney or cardiovascular disease.
› Verified 9 days ago
| Entity Name | Sutter Valley Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669846986 PECOS PAC ID: 9830094515 Enrollment ID: O20090311000335 |
News Archive
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
The predominance of men among patients admitted to psychiatric hospitals because of alcohol abuse has declined compared with 25 years ago in Iceland, while the gender gap for other substance use disorders has not changed, say researchers.
A research team led by Dr Alisoun Milne, a Senior Lecturer at the Tizard Centre, University of Kent, has identified weaknesses in the most widely employed dementia screening instrument currently used in primary care.
Cascade Chemistry, a leading contract research and manufacturing organization serving the pharmaceutical, materials, and chemical industries, today announced that it has been selected to produce the active pharmaceutical ingredient for clinical trial supplies of RBT-9, an investigational therapy entering a Phase 2 trial for the treatment of COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as kidney or cardiovascular disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John D Fichtenkort, MD 600 Coffee Rd, Modesto, CA 95355-4201 Ph: (209) 524-1211 | John D Fichtenkort, MD 600 Coffee Rd, Modesto, CA 95355-4201 Ph: (209) 524-1211 |
News Archive
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
The predominance of men among patients admitted to psychiatric hospitals because of alcohol abuse has declined compared with 25 years ago in Iceland, while the gender gap for other substance use disorders has not changed, say researchers.
A research team led by Dr Alisoun Milne, a Senior Lecturer at the Tizard Centre, University of Kent, has identified weaknesses in the most widely employed dementia screening instrument currently used in primary care.
Cascade Chemistry, a leading contract research and manufacturing organization serving the pharmaceutical, materials, and chemical industries, today announced that it has been selected to produce the active pharmaceutical ingredient for clinical trial supplies of RBT-9, an investigational therapy entering a Phase 2 trial for the treatment of COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as kidney or cardiovascular disease.
› Verified 9 days ago
John Joseph Gallo, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3800 Dale Rd, Modesto, CA 95356 Phone: 209-557-1000 | |
Pallavi Sharma, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 Coffee Rd, Modesto, CA 95355 Phone: 209-521-6097 | |
Phillip Michael Chan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1441 Florida Ave, Emergency Department, Modesto, CA 95350 Phone: 650-388-6383 | |
Dr. Paul Anthony Raykov, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4601 Dale Rd, Modesto, CA 95356 Phone: 209-735-5000 | |
Gregory P. Bowerman, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Coffee Rd, Modesto, CA 95355 Phone: 209-569-7600 | |
Christopher Samuel Lau, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4601 Dale Rd, Modesto, CA 95356 Phone: 209-735-6810 | |
Sushma V Shah, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4301 N Star Way, Modesto, CA 95356 Phone: 209-342-2300 Fax: 209-524-4240 |